Cellebrite DI (CLBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cellebrite DI (CLBT) has a cash flow conversion efficiency ratio of 0.170x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($82.23 Million) by net assets ($484.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cellebrite DI market capitalisation for the company's overall valuation and market capitalisation.
Cellebrite DI - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Cellebrite DI's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cellebrite DI Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellebrite DI ranked by their cash flow conversion efficiency. Explore cash flow quality index of Cellebrite DI to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
N/A |
|
National HealthCare Corporation
NYSE MKT:NHC
|
0.058x |
|
Enerjisa Enerji AS
IS:ENJSA
|
0.063x |
|
Shanghai Lingang Holdings Co Ltd A
SHG:600848
|
-0.002x |
|
Relay Therapeutics Inc
NASDAQ:RLAY
|
-0.080x |
|
Sinoma International Engineering Co Ltd
SHG:600970
|
0.096x |
|
LG Household & Healthcare
KO:051900
|
0.016x |
|
First BanCorp
F:OLWN
|
0.072x |
Annual Cash Flow Conversion Efficiency for Cellebrite DI (2019–2025)
The table below shows the annual cash flow conversion efficiency of Cellebrite DI from 2019 to 2025. View latest Cellebrite DI stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $484.32 Million | $168.96 Million | 0.349x | -11.31% |
| 2024-12-31 | $336.02 Million | $132.17 Million | 0.393x | -86.81% |
| 2023-12-31 | $34.21 Million | $102.06 Million | 2.983x | +970.84% |
| 2022-12-31 | $73.86 Million | $20.58 Million | 0.279x | +156.68% |
| 2021-12-31 | $-73.35 Million | $36.05 Million | -0.492x | -147.15% |
| 2020-12-31 | $63.80 Million | $66.51 Million | 1.042x | +280.11% |
| 2019-12-31 | $58.83 Million | $16.13 Million | 0.274x | -- |
About Cellebrite DI
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exp… Read more